MARKET

SNDX

SNDX

Syndax
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.02
+0.31
+3.56%
After Hours: 9.02 0 0.00% 16:00 01/17 EST
OPEN
8.79
PREV CLOSE
8.71
HIGH
9.14
LOW
8.74
VOLUME
186.28K
TURNOVER
--
52 WEEK HIGH
11.11
52 WEEK LOW
4.520
MARKET CAP
244.81M
P/E (TTM)
-4.2767
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SNDX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SNDX News

  • H.C. Wainwright Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $17
  • Benzinga.6d ago
  • Syndax Pharmaceuticals Announces A Strategic Outlook For 2020 Outlining Key Priorities For Its Broad Pipeline; The Company Anticipates Key Milestones For 2020
  • Benzinga.01/10 21:08
  • Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook
  • PR Newswire.01/10 21:05
  • Should You Avoid Syndax Pharmaceuticals, Inc. (SNDX)?
  • Insider Monkey.12/17/2019 21:39

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About SNDX

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.
More

Webull offers Syndax Pharmaceuticals Inc (SNDX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.